Form 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

_______________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  December 13, 2017

BIOMERICA, INC.

(Exact name of registrant as specified in its charter)

Delaware

0-8765

95-2645573

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

 

17571 Von Karman Ave. Irvine, California

92614

 

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code:  (949) 645-2111

Not Applicable

(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨          Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨          Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨          Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨          Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company      ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ¨

 

Item 5.07  Submission of Matters to a Vote of Security Holders.

Biomerica, Inc. (the “Company”) held its 2018 annual meeting (the “2018 Annual Meeting”) of stockholders of the Company on December 12, 2018 in Irvine, California. As of October 19, 2018, the record date for the 2018 Annual Meeting, the Company had 8,967,672 shares of its common stock outstanding and entitled to vote, of which 8,070,964 shares of the Company’s common stock were present in person or represented by proxy and entitled to vote at the 2018 Annual Meeting. The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the 2018 Annual Meeting.

Proposal No. 1:  The Company’s stockholders elected each of the six nominees named below to serve on the Company’s Board of Directors until the next annual meeting of stockholders of the Company and until his or her successor has been elected and qualified or until his or her earlier resignation, death or removal.

Nominee

Votes For

Votes Withheld

Broker Non-votes

Zackary Irani

3,339,836

14,827

4,946,515

Janet Moore

3,334,874

19,789

4,946,515

Allen Barbieri

3,340,998

13,665

4,946,515

Francis R. Cano, Ph.D.

3,335,935

18,728

4,946,515

Jane Emerson, M.D., Ph.D.

3,332,910

31,753

4,946,515

Mark Sirgo, Pharm. D.

3,302,036

52,627

4,946,515

Proposal No. 2:  The Company’s stockholders ratified the appointment of PFK, LLP as the Company’s independent public accounting firm for the fiscal year ending May 31, 2019.

Votes For

Votes Against

Votes Abstaining

Broker Non-Votes

7,774,960

199,249

96,755

--

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

   BIOMERICA, INC.

 

 

 

 

Date:  December 14, 2018

   By:

 

/s/ Zackary S. Irani

 

 

 

Zackary S. Irani
Chief Executive Officer